CVX logo

Carvolix SA Stock Price

ENXTPA:CVX Community·€191.9m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

CVX Share Price Performance

€0
-1.38 (-100.00%)
€0
-1.38 (-100.00%)
Price €0

CVX Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate risk with limited growth.

5 Risks
1 Reward

Carvolix SA Key Details

€5.3m

Revenue

€4.4m

Cost of Revenue

€916.0k

Gross Profit

€15.7m

Other Expenses

-€14.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.25
17.39%
-279.97%
107.8%
View Full Analysis

About CVX

Founded
2011
Employees
76
CEO
Sebastien Ladet
WebsiteView website
www.carvolix.eu

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026. Carvolix SA was founded in 2011 and is headquartered in Aix-en-Provence, France.

Recent CVX News & Updates

Recent updates

No updates